Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Espha Likely to Roll Out Urief, Iressa Authorized Generics: December Listing
Daiichi Sankyo Espha continues to fuel its authorized generic (AG) business with new portfolios as it is expected to launch AG versions of two brands upon the next generic listing in December: Kissei Pharmaceutical’s dysuria treatment Urief (silodosin) and AstraZeneca’s…
To read the full story
Related Article
- Authorized Generics for Iressa, Urief to Join NHI Price List; Nesp Biosame Skips Listing
December 13, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
- Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…